Phase 2Active, not recruiting
A Phase 2 Trial to Investigate Efficacy and Safety of Vipoglanstat in Women With Endometriosis (NOVA)
A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Investigate the Efficacy and Safety of 2 Doses of Vipoglanstat in Patients With Moderate to Severe Endometriosis-related Pain - the NOVA Trial
- Sponsor
- Gesynta Pharma AB (Industry)
- Enrollment
- 213 enrolled
- Conditions
- Endometriosis
- Interventions
- Vipoglanstat; Placebo
- Ages
- adults
- Registry
- NCT07260669, CTIS2025-522452-16-00
Full record on ClinicalTrials.gov
From the registry
The main objective of the trial is to evaluate the efficacy of vipoglanstat on endometriosis-related non-menstrual pelvic pain (NMPP).
Primary outcomes
- Percentage of Participants who meet the Predefined NMPP Responder Criteria from Baseline to Fourth Month of Treatment
History
Primary completion expected
Last registry update
Registered
Started